DeepMed Research

Recombinant Human Coagulation Factor Ⅷ

Generic Name: Recombinant Human Coagulation Factor Ⅷ

Indication: 用于血浆凝血因子Ⅷ（FⅧ）缺乏的甲型血友病（罕见病）治疗。在纠正或预防出血、急诊或择期手术中，本品起到暂时代替缺失的凝血因子的作用。

Clinical Trials

Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)

Phase 4

Recruiting

Conditions: Hemophilia a with Inhibitor

Interventions: Drug: Advate®

First Posted Date: 2025-03-07

Last Posted Date: 2025-03-07

Lead Sponsor: Runhui WU

Target Recruit Count: 110

Registration Number: NCT06864975

Locations: 🇨🇳
Beijing Children's hospitial, Beijing, Beijing, China

A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)

Phase 3

Recruiting

Conditions: Von Willebrand Disease (VWD)

Interventions: Biological: Vonicog Alfa
Biological: ADVATE

First Posted Date: 2022-10-17

Last Posted Date: 2025-03-12

Lead Sponsor: Takeda

Target Recruit Count: 24

Registration Number: NCT05582993

Locations: 🇮🇹
Azienda Ospedaliera Pediatrica Santobono Pausillipon, Napoli, Italy
🇮🇹
Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin (Torino), Italy
🇺🇸
Childrens Hospital of Michigan, Detroit, Michigan, United States

and more 7 locations

A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ，Fc Fusion Protein for Injection

Phase 1

Completed

Conditions: Hemophilia A

Interventions: Drug: ADVATE
Drug: FRSW107

First Posted Date: 2022-02-22

Last Posted Date: 2023-08-22

Lead Sponsor: Jiangsu Gensciences lnc.

Target Recruit Count: 13

Registration Number: NCT05251090

Locations: 🇨🇳
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, China
🇨🇳
Beijing Children's Hospital,Capital Medical University, Beijing, Beijing, China

and more 3 locations

A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Phase 1

Completed

Conditions: Severe Hemophilia A

Interventions: Drug: ADVATE
Drug: FRSW117

First Posted Date: 2021-04-29

Last Posted Date: 2023-09-08

Lead Sponsor: Jiangsu Gensciences lnc.

Target Recruit Count: 13

Registration Number: NCT04864743

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College., Tianjin, Tianjin, China
🇨🇳
Nanfang Hospital of Southern Medical University, Guangzhou, Guangzhou, China
🇨🇳
Jinan central hospital, Jinan, Shandong, China

and more 1 locations

A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Conditions: Hemophilia A

Interventions: Drug: ADVATE
Drug: FRSW107

First Posted Date: 2018-11-20

Last Posted Date: 2020-05-08

Lead Sponsor: Kaifeng Pharmaceutical (Group) Co., Ltd.

Target Recruit Count: 12

Registration Number: NCT03747653

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin, China
🇨🇳
Hematology Department, Beijing Children's Hospital, Capital Medical University, Beijing, China
🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China

and more 2 locations

Drug Use Investigation of Kovaltry in Hemophilia A Patients

Active, not recruiting

Conditions: Hemophilia A

Interventions: Drug: Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973)

First Posted Date: 2016-10-21

Last Posted Date: 2025-05-08

Lead Sponsor: Bayer

Target Recruit Count: 231

Registration Number: NCT02941783

Locations: 🇯🇵
Many Locations, Multiple Locations, Japan

Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate

Phase 1

Completed

Conditions: Hemophilia A

Interventions: Drug: BAY81-8973
Drug: Advate

First Posted Date: 2015-06-26

Last Posted Date: 2016-02-17

Lead Sponsor: Bayer

Target Recruit Count: 18

Registration Number: NCT02483208

Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens

Phase 4

Conditions: Severe Haemophilia A

Interventions: Drug: ADVATE [Antihemophilic Factor (Recombinant)]

First Posted Date: 2014-12-11

Last Posted Date: 2014-12-11

Lead Sponsor: St. James's Hospital, Ireland

Target Recruit Count: 20

Registration Number: NCT02314325

Locations: 🇮🇪
St. James's Hospital, Dublin, Ireland

Prospective Biomarkers of Bone Metabolism in Hemophilia A

Phase 3

Completed

Conditions: Hemophilia
Bone Disease

Interventions: Drug: Advate

First Posted Date: 2014-12-03

Last Posted Date: 2020-04-01

Lead Sponsor: Oregon Health and Science University

Target Recruit Count: 16

Registration Number: NCT02306694

Locations: 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States

Evaluate Efficacy and Safety of ADVATE in the Standard Prophylaxis Treatment of Severe or Moderately Severe Hemophilia A

Not Applicable

Conditions: Hemophilia A

Interventions: Drug: ADVATE

First Posted Date: 2014-11-04

Last Posted Date: 2014-11-04

Lead Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Target Recruit Count: 15

Registration Number: NCT02282410

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy